Cannvas MedTech (CSE:MTEC), a leading digital cannabis educator and business technology company, is pleased to report it continues toward its goal of becoming the leading social and census data collection agency of the cannabis industry. With over one million cannabis consumer data points collected since the launch of its digital cannabis education platform Cannvas.Me, Cannvas is well-positioned to accelerate its data collection and analysis within the industry.

“With the breadth of data we collect from the cannabis industry, from Canada to Germany and other countries across the world where we have a growing user base, Cannvas Data is positioning itself to deliver timely, accurate and relevant information to organizations looking to tailor their production and marketing efforts to an ever-evolving audience of consumers, health advocates, physicians, lawmakers, investors and producers,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “The idea is that companies can drill down to determine the needs of a retired 65-year-old man in Montreal with sleep issues, compared to those of a working 65-year-old man in rural Alberta with chronic pain, and deliver information and products pertinent to those conditions. We as an industry must deliver a personalized experience to our consumer base if we are to continue increasing our credibility.”


With thousands of users signed up and active on the Cannvas.Me platform since its October 2018 launch, the site continues to experience sustained growth as it delivers free and physician-backed cannabis education using artificial intelligence to contextualize and adapt to its users while collecting valuable industry and customer data points. The Company’s Cannvas Data branch uses the same advanced technology to closely analyze and process data points to reveal highly-focused and relevant cannabis industry insights.

“Our data sets us apart within the industry, as our Cannvas.Me platform continually collects global data relevant to cannabis sectors that we can then feed back into the industry,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Expansion of our user base through key partnerships within and outside the cannabis industry translates into a richer set of data and insights into cannabis consumption, a key revenue-generating driver of our business.”

Cannvas Data uses machine-learning algorithms and artificial intelligence (AI) to analyze cannabis industry trends, opportunities and challenges and create detailed reports for a range of sectors including education, medical and health sciences, government and the cannabis sector itself. Through the partnership network established by Cannvas.Me with recognized healthcare and education providers, such as Namaste, Hi-Jane and Advica Health, Cannvas Data is increasing the amount of data it processes nearly every day. NamasteMD alone brings a reach extending across 20 countries with a database of nearly two million users. The result is an ongoing anonymized analysis of what cannabis consumers across Canada are seeking out, from education and methods of ingestion to products, producers and prescriptions.

Through Cannvas Health, the Company has entered into agreements with leading health care and education organizations, as well as dispensaries and cannabis brands, to provide white label solutions for digital cannabis education opportunities powered by the Cannvas.Me platform. This exposure expands the ability of Cannvas Data to comb through vast networks with millions of users volunteering their cannabis inquiries and habits as they navigate learning modules and informational articles on the potential health benefits of cannabis as an alternative treatment. Aiming to be among the international authorities of unbiased and arm’s-length information on the cannabis sector, Cannvas Data continues to work with those in the industry to paint a clearer picture of the marketplace and its needs at present and in the future.

Cannvas MedTech also recently joined the Global Cannabis Partnership (GCP), a collective of leaders in the government-sanctioned, adult-use recreational cannabis industry, as a Member organization. The goal of the GCP is to develop an international standard for the safe and responsible production, distribution and consumption of legal recreational cannabis and help shape the face of social responsibility in the cannabis industry. Its main objectives are to build credibility for government agencies, industry and partners through responsible practices, align and leverage common principles and practices across diverse jurisdictions, and help partners mitigate negative impacts and leverage best practices from within and outside the industry to protect and enhance social licence to operate, with a view to minimizing harm.

Additionally, the Company issued a total of 58,703 common shares (the “Shares”) at a deemed value of $0.30 per Share to certain persons for certain consulting fees owed totaling approximately $17,610.90. Cannvas also issued an aggregate of 1,000,000 Shares of the Company at a deemed value of $0.30 per Share to certain related parties of the Company, pursuant to the achievement of certain milestones and in accordance with their respective consulting agreements.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.

For additional information:
CannvasMedTech.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

For further information: Investor Relations: Renmark Financial Communications Inc., Shushu Feng: sfeng@renmarkfinancial.com, Tel: (416) 644-2020 or (212) 812-7680

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

HempFusion Wellness Inc . (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (“ HempFusion ” or the “ Company ”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, announced today it will report its financial results for the first quarter ended March 31, 2021 at 4 p.m., Eastern Time, on Monday, May 17, 2021 followed by a 4:15 p.m., Eastern Time conference call and webcast with a question-and-answer session.

To participate in the call, please dial 888-506-0062. For international callers, dial 973-528-0011. Use Participant Code: 795055

Keep reading... Show less

Partnership Aimed at Delivering Psychedelic
Capsule for Dosing Study in Human Clinical Trial

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, and Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, have met another early milestone in the development of an initial all natural psilocybin extract.

Keep reading... Show less

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus“) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.

Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary (“Impact”), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation, and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab in British Columbia, Canada.

Keep reading... Show less

Poised for Rapid Growth in Europe’s Largest Medical Cannabis Market

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH (“Adven”) has launched its own range of medical cannabis products in Germany Europe’s largest medical cannabis market.  The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THCCBD formulations in both oil and flower formats, addressing a wide range of patient needs. Germany is Europe’s largest medical cannabis market and is expected to be worth US$2.1 billion by 2025 1 .

Keep reading... Show less

After announcing placements of Fit Soda™ in well-known regional grocery chains such as HEB and Sprouts, Koios is pleased to announce that its Fit Soda™ functional beverage is now available in all Food Lion supermarkets, a chain which operates more than 1,100 grocery stores in the eastern United States. As the sugar-free beverage category continues to grow, Coca-Cola recently announced its prediction that its “Coke Zero Sugar” variety will be the firm’s biggest driver of growth in 2021 and beyond. Based on these industry trends, Koios’ objective is to strategically grow the market presence of Fit Soda™, which sold approximately 700,000 units in 2020, its first full calendar year on the market.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that as of Monday, May 10, 2021 all four flavours of Fit Soda ™ are being carried in more than 1,100 supermarkets operated by Food Lion LLC (“Food Lion”), a multistate grocery chain based in Salisbury, North Carolina. Since November 2020, the Company has placed its Fit Soda ™ functional beverage product with several other regional chains across the United States to include HEB (as announced in a November 4, 2020 press release), all three banners of Massachusetts-based Roche Bros. (as announced in a February 24, 2021 press release), and Sprouts Farmers Market (as announced in a March 4, 2021 press release). Approximately 700,000 units of Fit Soda ™ were sold during the product’s first full calendar year of retail sales in 2020 between retail placements in grocery and foodservice outlets, as well as direct-to-consumer sales through the Koios online store. With the addition of Fit Soda ™ to all 1,100 locations of Food Lion across ten U.S. states, the Company believes there is significant opportunity for Fit Soda ™ to have its best year yet in 2021.

Keep reading... Show less